2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.12C.01 Sotorasib vs Adagrasib: Matching-adjusted Indirect Comparison in Prior Treated KRAS G12C Advanced Non-Small Cell Lung Cancer

EP.12C.01 Sotorasib vs Adagrasib: Matching-adjusted Indirect Comparison in Prior Treated KRAS G12C Advanced Non-Small Cell Lung Cancer

Back to course

Pdf Summary

This study investigates the efficacy of two treatments, sotorasib and adagrasib, for advanced non-small-cell lung cancer (NSCLC) with the KRAS G12C mutation, utilizing a matching-adjusted indirect comparison (MAIC) due to the absence of direct comparative trials. Both drugs are KRAS G12C inhibitors and have been approved for use in previously treated patients.<br /><br />The analysis draws data from trials: sotorasib's CodeBreaK 100 and adagrasib's KRYSTAL-1. The methodology involved aligning patient characteristics across trials and adjusting results to identify effective sample sizes and outcomes. Key factors included sex, race, ECOG performance status, and the presence of metastatic disease.<br /><br />Results indicate no statistically significant difference between the drugs in terms of overall survival (OS), progression-free survival (PFS), and objective response rate (ORR), both in the general population and the North American subgroup. For instance, sotorasib presented an 8% lower risk of death compared to adagrasib, but this was not statistically significant.<br /><br />The findings were consistent across sensitivity analyses, which incorporated additional covariates such as bone and liver metastases, smoking status, and prior therapies. However, limitations exist, including the MAIC's assumption of accounted effect modifiers and prognosis factors, potential biases from digitized data curves, and the applicability limited to the trial populations rather than a broader real-world context.<br /><br />The study suggests that future research incorporating phase 3 trial data, especially from the pending KRYSTAL-12 trial, could provide further insights. Despite a few limitations, the study's conclusion is that current treatments show similar efficacy, offering clinically relevant information for treatment decisions in this patient subset.

Asset Subtitle

Divyan Chopra

Meta Tag

Speaker Divyan Chopra

Topic Metastatic Non-small Cell Lung Cancer – Targeted Therapy

Keywords

sotorasib

adagrasib

NSCLC

KRAS G12C mutation

MAIC

CodeBreaK 100

KRYSTAL-1

overall survival

progression-free survival

objective response rate